Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate
- 1 July 1986
- journal article
- conference paper
- Published by Springer Nature in Calcified Tissue International
- Vol. 39 (4), 226-229
- https://doi.org/10.1007/bf02555208
Abstract
4-amino-1-hydroxybutylidene-1,1-bis-phosphonate (AHButBP) was given intravenously (2.5–25 mg/day for 4 days) to 14 patients with Paget's disease of bone, five of whom had been treated with dichloromethylidene bisphosphonate (Cl2MBP) 32 months earlier. In the nine patients who had not been treated previously with bisphosphonates, the short course of AHButBP induced a suppression of serum alkaline phosphatase and urinary hydroxyproline values down to 30% of initial values. The biochemical suppression of the disease was sustained for 2–18 months and the time to relapse did correlate to the logarithm of the dose (P2MBP, irrespective of the degree of relapse. Thus the degree of suppression of Paget's disease of bone, achievable after treatment with bisphosphonates, seems to be constant for each patient, such that normal levels of serum alkaline phosphatase and urinary hydroxyproline cannot usually be attained in patients with extremely active disease.This publication has 14 references indexed in Scilit:
- INTRAVENOUS CLODRONATE IN THE TREATMENT AND RETREATMENT OF PAGET'S DISEASE OF BONEThe Lancet, 1985
- Use of Dichloromethylene Diphosphonate in Metastatic Bone DiseaseNew England Journal of Medicine, 1983
- Differential Action of the Bisphosphonates (3-Amino-1-Hydroxypropylidene)-1,1-Bisphosphonate (APD) and Disodium Dichloromethylidene Bisphosphonate (Cl2MDP) on Rat Macrophage-mediated Bone Resorption In VitroJCI Insight, 1982
- Paget's bloom of bone : Diagnosis and managementMetabolic Bone Disease and Related Research, 1981
- Apd in paget's disease of bone role of the mononuclear phagocyte system?Arthritis & Rheumatism, 1980
- Use of etidronate (ehdp) in paget's disease of boneArthritis & Rheumatism, 1980
- EFFECT OF DICHLOROMETHYLENE DIPHOSPHONATE IN PAGET'S DISEASE OF BONE AND IN HYPERCALCÆMIA DUE TO PRIMARY HYPERPARATHYROIDISM OR MALIGNANT DISEASEThe Lancet, 1980
- INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 1979
- TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 1979
- Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkeyToxicology and Applied Pharmacology, 1972